New Risk-Guided approach aims to boost cure rates for childhood leukemia

NCT ID NCT03020030

First seen Jan 27, 2026 · Last updated May 15, 2026 · Updated 17 times

Summary

This study is for children and teens newly diagnosed with acute lymphoblastic leukemia (ALL), a blood cancer that is fatal without treatment. The trial uses an updated set of risk factors to tailor how strong the chemotherapy should be, aiming to give each child the best chance for cure. It also tests a new way of dosing a key chemotherapy drug, pegaspargase, by checking drug levels in the blood and adjusting the dose as needed. About 560 participants will be followed to see if this personalized approach improves cure rates and reduces side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, PEDIATRIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Boston Children's Hospital

    Boston, Massachusetts, 02115, United States

  • Centre Hospitalier U. de Quebec

    Québec, Quebec, Canada

  • Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian

    New York, New York, 10032, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Hasbro Children's Hospital / Rhode Island Hospital

    Providence, Rhode Island, 02903, United States

  • Hospital Sainte Justine, University of Montreal

    Montreal, Quebec, Canada

  • Montefiore Medical Center

    The Bronx, New York, 10467, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey, 08903, United States

Conditions

Explore the condition pages connected to this study.